PMID- 12694665
OWN - NLM
STAT- MEDLINE
DCOM- 20030515
LR  - 20190826
IS  - 0090-8258 (Print)
IS  - 0090-8258 (Linking)
VI  - 89
IP  - 1
DP  - 2003 Apr
TI  - No alteration in NK function or zeta chain expression in NK and T cells of 
      cervical cancer patients.
PG  - 120-8
AB  - OBJECTIVE: To investigate in vitro natural killer (NK) cell activity and 
      expression of signal-transducing zeta chains in patients with cervical cancer. 
      PATIENTS AND METHODS: Experiments were performed with frozen lymphocytes from 
      patients at all disease stages and from healthy controls. Thawed NK were 
      activated by overnight incubation in interferon-gamma (IFN-gamma); activity 
      against two target cell lines was assessed by 4-h (51)Cr release assay. Targets 
      chosen were K562, an erythroleukemic cell line, and a cervical carcinoma cell 
      line designated 808. T and NK cell zeta chain expression was measured by flow 
      cytometry. RESULTS: Patients' NK were found to be as cytotoxic as those of normal 
      controls against cell lines K562 and 808. Patient T and NK cells did not show 
      significant down-regulation of the zeta chain. CONCLUSIONS: We have found no 
      evidence to suggest that loss of zeta chains is a mechanism for immunocompromise 
      in patients with cervical carcinoma. IFN-recoverable patient NK activity is not 
      reduced compared to matched controls. This may be clinically relevant since NK 
      are active against cells exhibiting class I human leukocyte antigen (HLA) 
      down-regulation and many cervical cancers show loss of HLA.
FAU - Onon, Toli S
AU  - Onon TS
AD  - Department of Immunology, Paterson Institute for Cancer Research, Christie 
      Hospital, Manchester, United Kingdom. toli.onon@srht.nhs.uk
FAU - Kitchener, Henry C
AU  - Kitchener HC
FAU - Duggan-Keen, Margaret
AU  - Duggan-Keen M
FAU - Stern, Peter L
AU  - Stern PL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (CD3 Complex)
RN  - 0 (CD3 antigen, zeta chain)
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Receptors, IgG)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Age Factors
MH  - CD3 Complex/biosynthesis/*immunology
MH  - Chromium Radioisotopes
MH  - Cytotoxicity, Immunologic
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Interferon-gamma/pharmacology
MH  - K562 Cells
MH  - Killer Cells, Natural/*immunology/metabolism
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Receptors, IgG/biosynthesis/*immunology
MH  - T-Lymphocytes/*immunology/metabolism
MH  - Uterine Cervical Neoplasms/*immunology/metabolism/pathology
EDAT- 2003/04/16 05:00
MHDA- 2003/05/16 05:00
CRDT- 2003/04/16 05:00
PHST- 2003/04/16 05:00 [pubmed]
PHST- 2003/05/16 05:00 [medline]
PHST- 2003/04/16 05:00 [entrez]
AID - S009082580300009X [pii]
AID - 10.1016/s0090-8258(03)00009-x [doi]
PST - ppublish
SO  - Gynecol Oncol. 2003 Apr;89(1):120-8. doi: 10.1016/s0090-8258(03)00009-x.